Catalyst Event
Celltrion Inc (068270) · Other
From Akros Korea Shareholder Return High Dividend Index (AKSRHD)
3/25/2026, 12:00:00 AM
Announced a license-in agreement with KoBioLabs on March 25, 2026, for three microbiome-based drug candidates for gastrointestinal diseases, with a total potential value of up to KRW 205.2 billion, scheduled.
Korean Translation
2026년 3월 25일 고바이오랩으로부터 위장관 질환 관련 마이크로바이옴 기반 신약 후보물질 3개를 도입하는 기술도입 계약을 체결할 예정됨.
Related Recent Events
Samsung Card Co Ltd (029780) · Earnings Release
Samsung Card is scheduled to release its next earnings report on 2026-04-28; likely low impact because it is a routine quarterly catalyst scheduled.
4/28/2026, 12:00:00 AM
Kia Corporation (000270) · Other
Kia CEO Investor Day on 2026-04-09 to update electrification strategy and shareholder return policy; medium impact estimated because capital allocation and long-term targets can move valuation, scheduled.
4/9/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
The company will cancel 9.11 million treasury shares (approx. 4% of total issued shares) worth about KRW 1.7 trillion on April 1, 2026, scheduled.
4/1/2026, 12:00:00 AM
Korean Reinsurance Company (003690) · Other
Cancellation of 18.1 million treasury shares, valued at approximately 245.4 billion KRW, on March 31, 2026 scheduled
3/31/2026, 12:00:00 AM
COWAY Co Ltd (021240) · Other
The 37th Annual General Meeting of Shareholders is scheduled for 2026-03-31. A proxy fight is expected between management and activist fund Align Partners over the appointment of an audit committee member. High importance is estimated as proxy contests typically drive price volatility over 10% expected.
3/31/2026, 12:00:00 AM
Korean Reinsurance Company (003690) · Other
Annual cash dividend of 570 KRW per share with ex-dividend date on March 31, 2026 scheduled
3/31/2026, 12:00:00 AM